US approval for ULTOMIRIS® for gMG

ULTOMIRIS® (ravulizumab-cwvz) approved in the US for Adults with Generalised Myasthenia Gravis First and only long-acting C5 complement inhibitor to demonstrate clinical improvement in patients with generalised myasthenia gravis ULTOMIRIS showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks April 28, 2022:…

Biogen withdraws marketing authorisation application for aducanumab for Alzheimer’s disease

Biogen has informed the European Medicines Agency (EMA) that it is withdrawing its application for marketing authorisation for aducanumab for the treatement of Alzheimer’s disease The EMA had previously found on 16 December 2021 that the benefits of aducanumab did not outweigh its risks and recommended refusing marketing authorisation. Biogen then requested a re-examination. Following…

Manoj Sivan to deliver keynote lecture at AFRM conference

The Australasian Faculty of Rehabilitation Medicine has invited Dr Manoj Sivan to deliver the keynote lecture at its conference in Melbourne, Australia on 12 May, 2022. Dr Sivan one of only three UK rehabilitation specialists to have ever been invited to give this prestigious lecture. The AFRM’s annual keynote lecture was named the George Burniston…

ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results

Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results Results demonstrate safety and efficacy of ZTALMY, first FDA-approved treatment for seizures associated with CDKL5 deficiency disorder in patients two years and older Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of therapeutics to treat seizure disorders, announced on…

Diroximel fumarate receives positive recommendation from NICE for oral treatment of relapsing-remitting multiple sclerosis (RRMS)

Diroximel fumarate is a next generation, at-home, oral fumarate treatment, with established efficacy and well-characterised safety, for people living with relapsing-remitting multiple sclerosis (RRMS)1,2 Phase 3 data and real-world evidence (n=263, based in the US) have demonstrated that treatment with diroximel fumarate results in low discontinuation rates due to its gastrointestinal (GI) tolerability profile3,7  The…

Phase 2 LUMINARY Study of SAGE-718 in Patients with Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease

Sage Therapeutics presents promising results from LUMINARY Study Data presented during the Emerging Science Session at the American Academy of Neurology’s Annual Meeting, April 2022 The LUMINARY Study is a Phase 2, open-label study evaluating the safety, tolerability and efficacy of SAGE-718 once daily in individuals with mild cognitive impairment and mild dementia due to…

Liraglutide Improves Non-Motor Function and Activities of Daily Living in Patients with Parkinson’s disease

Abstract of poster presented at the AAN 2022, by Michele Tagliati, MD, FAAN Treatment with liraglutide improves critical features of PD, including non-motor symptoms and activities of daily living. These results validate similar outcomes reported with other GLP-1 agonists in PD and offer new strategies to treat the constellation of PD symptoms. BackgroundInsulin resistance (IR)…

Cenobamate (ONTOZRY®) now available in The Netherlands

Angelini Pharma, an international pharmaceutical company part of the privately held Italian Angelini Group announced on 4 April 2022 that ONTOZRY® (cenobamate) is now available in the Netherlands for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adults patients who have not been adequately controlled despite an history of treatment with…

UPLIZNA® (inebilizumab-cdon) Effective for People with Newly-Presenting Neuromyelitis Optica Spectrum Disorder (NMOSD)

Horizon Therapeutics plc announced on 31 March, 2022 the presentation of a post-hoc analysis from the N-MOmentum Phase 3 pivotal trial of UPLIZNA, showing that the medicine was safe and effective in NMOSD patients who were treated with UPLIZNA after having only one attack. These data were presented during a poster session at the American Academy…